Trials / Suspended
SuspendedNCT04523727
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
- Status
- Suspended
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Keryx Biopharmaceuticals · Industry
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ferric citrate | oral tablets |
Timeline
- Start date
- 2022-06-16
- Primary completion
- 2026-12-01
- Completion
- 2027-10-01
- First posted
- 2020-08-24
- Last updated
- 2026-02-17
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04523727. Inclusion in this directory is not an endorsement.